1. Home
  2. TNXP vs TMCI Comparison

TNXP vs TMCI Comparison

Compare TNXP & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • TMCI
  • Stock Information
  • Founded
  • TNXP 2007
  • TMCI 2014
  • Country
  • TNXP United States
  • TMCI United States
  • Employees
  • TNXP N/A
  • TMCI N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • TNXP Health Care
  • TMCI Health Care
  • Exchange
  • TNXP Nasdaq
  • TMCI Nasdaq
  • Market Cap
  • TNXP 335.6M
  • TMCI 344.1M
  • IPO Year
  • TNXP N/A
  • TMCI 2021
  • Fundamental
  • Price
  • TNXP $51.35
  • TMCI $6.89
  • Analyst Decision
  • TNXP Buy
  • TMCI Hold
  • Analyst Count
  • TNXP 1
  • TMCI 5
  • Target Price
  • TNXP $70.00
  • TMCI $8.60
  • AVG Volume (30 Days)
  • TNXP 1.8M
  • TMCI 388.1K
  • Earning Date
  • TNXP 08-11-2025
  • TMCI 08-07-2025
  • Dividend Yield
  • TNXP N/A
  • TMCI N/A
  • EPS Growth
  • TNXP N/A
  • TMCI N/A
  • EPS
  • TNXP N/A
  • TMCI N/A
  • Revenue
  • TNXP $9,831,000.00
  • TMCI $213,751,000.00
  • Revenue This Year
  • TNXP $22.87
  • TMCI $10.61
  • Revenue Next Year
  • TNXP $711.66
  • TMCI $10.41
  • P/E Ratio
  • TNXP N/A
  • TMCI N/A
  • Revenue Growth
  • TNXP N/A
  • TMCI 7.67
  • 52 Week Low
  • TNXP $6.76
  • TMCI $4.54
  • 52 Week High
  • TNXP $130.00
  • TMCI $10.79
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 55.76
  • TMCI 69.82
  • Support Level
  • TNXP $42.12
  • TMCI $5.17
  • Resistance Level
  • TNXP $69.97
  • TMCI $7.04
  • Average True Range (ATR)
  • TNXP 6.06
  • TMCI 0.51
  • MACD
  • TNXP 1.01
  • TMCI 0.16
  • Stochastic Oscillator
  • TNXP 45.73
  • TMCI 80.51

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Share on Social Networks: